Table 1 MRR and PGIC at Month 1
Eptinezumab 100 mg | Eptinezumab 300 mg | Placebo | |
|---|---|---|---|
MRR | |||
n | 356 | 350 | 366 |
≥ 75% | 110 (30.9) | 129 (36.9) | 57 (15.6) |
50–< 75% | 84 (23.6) | 83 (23.7) | 75 (20.5) |
25–< 50% | 59 (16.6) | 58 (16.6) | 81 (22.1) |
< 25% | 103 (28.9) | 80 (22.9) | 153 (41.8) |
PGIC | |||
n* | 328 | 329 | 330 |
Very Much Improved | 41 (12.5) | 81 (24.6) | 27 (8.2) |
Much Improved | 110 (33.5) | 112 (34.0) | 80 (24.2) |
Minimally Improved | 103 (31.4) | 76 (23.1) | 82 (24.8) |
No Improvement† | 74 (22.6) | 60 (18.2) | 141 (42.7) |